vimarsana.com

Page 19 - மருத்துவ புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Imugene Ltd has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal

Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The final PFS readout is expected within months. Imugene Ltd’s (ASX:IMU) (OTCMKTS:IUGNF) Phase 1b clinical trial data for its B cell peptide cancer immunotherapy HER-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research. The article - Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001 - is authored by Professor Dr Ursula Wiedermann from the Medical University Vienna and study investigators. 

New test detects residual cancer DNA in the blood without relying on tumor data

 E-Mail BOSTON - After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in Clinical Cancer Research, a team led by investigators at Massachusetts General Hospital (MGH) has evaluated the first tumor-uninformed test that detects cancer DNA circulating in the blood of patients following treatment. The test, called Guardant Reveal, developed by precision oncology company Guardant Health, is tumor-uninformed because, unlike previous tests for circulating tumor DNA (ctDNA) in the blood, this test does not require knowing the particular mutations that were present in the patient s tumor.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.